Faculty Advisor

Adams, David S.

Abstract

Antibody-drug conjugates (ADCs) are a type of targeted therapy for killing cancer cells that are composed of an antibody directed against a tumor antigen linked to a potent cytotoxic drug that kills the cell. ADCs have great potential, and in some cases have been shown to cause complete cancer remissions. Although the targeting idea appears to be simple, to date only two ADC drugs have received FDA approval. The goal of this IQP project was to evaluate ADC technology by assessing its technical and regulatory problems in order to help determine the obstacles for gaining approval. We conclude that the approved ADCs had well-chosen target antigens and years of research prior to approval. We recommend that ADC research be continued to identify other adequate target antigens.

Publisher

Worcester Polytechnic Institute

Date Accepted

August 2017

Project Type

Interactive Qualifying Project

Accessibility

Unrestricted

Advisor Department

Biology and Biotechnology

Share

COinS